Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)

1. Vukusic, S.
2. Brassat, D.
3. de Seze, J.
4. Izquierdo, G.
5. Lysandropoulos, A.
6. Moll, W.
7. Vanopdenbosch, L.
8. Arque, M.J.
9. Kertous, M.
10. Rufi, P.
11. Oreja-Guevara, C.